【4565】そーせいG 441 【新年度入り：2018年度から12月期決算へ移行】
■ このスレッドは過去ログ倉庫に格納されています
>>131
仮に今現在の取得単価が五ケタでも利確してるんだろうし現物だし問題無いでしょ？
糞貧乏人に心配されてる五味さんも色々大変だなｗ ※Heptares Therapeutics Zurich Limited - Schlieren: "Group Leader Protein Biochemistry - Heptares Zurich". (4/3up)
Heptares is a Drug Discovery Company working on G protein-coupled receptors (GPCRs) involved in CNS and metabolic diseases.
Our unique structure-based approach in discovering therapeutic agents for these diseases relies on a proprietary technology to stabilize GPCRs,
enabling their purification for structural and biophysical studies.
The company works in collaboration with major global pharmaceutical companies on both small molecule and antibody discovery programmes;
and is also developing its own pipeline of proprietary molecules.
The most advanced of these are now in clinical studies with others moving towards clinical development.
We are currently seeking an experienced protein biochemist to grow and lead our newly established protein biochemistry group
at our site in Zurich working towards GPCR structure determination to enable drug discovery efforts.
"Group Leader Protein Biochemistry Heptares Zurich"
Our preferred candidate will have the following profile:
・PhD in biochemistry or related discipline
・Proven ability to grow, teach and lead a team (PhD level and technician)
・Experienced in molecular biology
・Experienced in membrane protein expression methods in mammalian and insect cells
・Experienced in membrane protein purification using AEKTA Pure systems
・Excellent knowledge of protein QC and troubleshooting
・Experienced in preparation of protein for membrane protein crystallization (lipidic cubic phase and vapor diffusion)
・Experience in setting up crystallization using automated systems would be an advantage
・Ability to work flexibly within a team whilst being highly self-motivated and work independently
・Analytical thinking and good problem-solving skills
・Excellent organizational and time management skills as well as the ability to work to strict deadlines
・Experienced in hands-on teaching and training of junior staff
・Fluency in oral and written English; a knowledge of German is preferred The successful candidate will be expected to work independently and manage staff, and the role will include the following responsibilities:
・Lead and line manage staff of the protein biochemistry group (initial hands-on experience is required)
・Grow the team from currently 2 FTEs to 5 FTEs by 2020
・Train and teach junior staff and set individual and group objectives
・Close interaction with protein biochemistry group in the UK
・Coordinate requirements with HZ Management
・Coordination of work and QC to guarantee transfer of protein for crystallization
・Careful documentation of experimental work; and,
・Work closely with molecular biologists, protein expression scientists, crystallographers and pharmacologists to help advance the multidisciplinary drug development projects
・Develop and optimize local protein QC capabilities – establish local opportunities
Groups responsibilities are:
・Characterization of GPCRs expression in membrane and in solubilized form
・Coordination of material requirements between expression and purification
・Construct engineering to optimize GPCRs for crystallization
・Purification of GPCRs and biochemical characterization using a range of analytical techniques such as size exclusion chromatography - develop and optimize processes
・Progression of purified material into crystallization
This is an exceptional opportunity to participate in growing and shaping our site new site in Zurich.
The closing date for applications is 5th of May 2018. ※Heptares Therapeutics Zurich Limited - Schlieren: "Junior Protein Biochemist – Heptares Zurich". (4/3up)
Company Description:
Heptares is a Drug Discovery Company working on G protein-coupled receptors (GPCRs) involved in CNS and metabolic diseases.
Our unique structure-based approach in discovering therapeutic agents for these diseases relies on a proprietary technology to stabilize GPCRs, enabling their purification for structural and biophysical studies.
The company works in collaboration with major global pharmaceutical companies on both small molecule and antibody discovery programmes; and is also developing its own pipeline of proprietary molecules.
The most advanced of these are now in clinical studies with others moving towards clinical development.
Position
We are currently seeking an experienced protein biochemist to join our site in Zurich working towards GPCR structure determination to enable drug discovery efforts.
The successful candidate will be expected to work independently as a member of our newly established protein biochemistry group, and the role will include the following responsibilities:
・Cloning of plasmid constructs for expression of crystallization constructs;
・Expression of GPCRs in insect and mammalian cells;
・Characterization of GPCRs expression in membrane and in solubilized form;
・Construct engineering to optimize GPCRs for crystallization;
・Purification of GPCRs and biochemical characterization using a range of analytical techniques such as size exclusion chromatography
・Careful documentation of experimental work; and,
・Work closely with the company’s project based interdisciplinary task-forces of molecular biologists, protein expression scientists, crystallographers and pharmacologists to help advance our drug development efforts.
Requirements:
Our preferred candidate will have the following profile:
・PhD in biochemistry or equivalent (3 years’ experience in membrane protein biochemistry)
・Experience in molecular biology
・Experience in membrane protein expression methods in mammalian and insect cells;
・Experience in membrane protein purification using AEKTA Pure systems;
・Experience in preparation of protein for membrane protein crystallization would be of advantage
・Ability to work flexibly within a team whilst being highly self-motivated and work independently;
・Analytical thinking and good problem solving skills;
・Excellent organizational and time management skills as well as the ability to work to strict deadlines;
・Fluency in oral and written English; a knowledge of German is preferred
Other information:
This is an exceptional opportunity to participate in pioneering science with an Industry-leading Drug Discovery company.
The closing date for applications is 5h of May 2018. >>133
糞貧乏人のお前に言われても説得力ねえよ 五味さんが抜けられるのは二万くらいでしばらく安定しないとならんからまだまだ数年先の話だわな Events update:
※CECAM Workshops: CompAllo: Towards a Unified Approach to the Analysis and Design of Allostery: Lausanne, Switzerland: April 9-11, 2018.
・Invited Speaker: Rob Cooke (Heptares).
※3rd North American SMALP Conference: Overcoming Bottlenecks in Membrane Biology: Alberta Canada, April 11, 2018.
・April 11, 14:10-14:30, "Structure-Based Drug Design of GPCRs": Jana Broecker (Heptares).
※UK-QSAR Group and Molecular Graphics and Modelling Society Joint Conference "Structure-Activity Relationships", University of Cardiff, UK: April 11-12, 2018.
・Apr 12, 14:30, "Beyond the Happy Water - recent advances in the quantification of contributions": Ben Tehan (Heptares).
※EASL(European Association for the Study of the Liver) International Liver Congress: Paris, France, 11-15 April 2018.
・MiNA Therapeutics.
※大阪大学蛋白質研究所：第2回感覚器研究イニシアチブ・シンポジウム：4月15日13：00、大阪大学吹田キャンパス/銀杏会館
・16:53-17:23 「幻視の発現機構」 森悦朗：大阪大学大学院連合小児発達学研究科行動神経学・神経精神医学寄附講座(Heptares寄附講座)教授
※Oxford Global Conferences, 5th Annual Peptides Congress: London, UK: April 16-17, 2018.
・Cedric Fiez-Vandal, Senior Scientist (Heptares).
※ASPET Annual Meeting at Experimental Biology 2018: San Diego, CA, USA, Apr 21-25, 2018.
・Apr 24, "X-Ray Structures of GPCRs Provide Insights into New Binding Sites for Drug Discovery": Jon Mason (Heptares).
※Annual Conference for the Advancement of Clinical Research in Israel: April 24, 2018.
・11:40, Zami Aberman, Chairman & Co-CEO, Pluristem. ※Basel Area, Swiss Life Sciences Event: "Between Basic Research and Biotech Entrepreneurship": Andreas Pluckthun (co-founder of Morphosys, Molecular Partners and G7 Therapeutics (now Heptares-Zurich)).
・Apr 24, 19:00-20:00, "Andreas Pluckthun": He recounts how he successfully co-founded several biotech companies and how the ecosystem for startups has evolved in the last 20 years.
※TIDES: Oligonucleotide and Peptide Therapeutics 2018: Boston, MA, USA, May 7-10, 2018.
・May 10, 10:45-11:15, mRNA, CRISPR and Hot Topics in Oligonucleotides: "RNA Activation in NASH, Liver Failure and Hepatocellular Carcinoma": Nagy Habib, MD Head of R&D, MiNA Therapeutics.
※World Advanced Therapies & Regenerative Medicine Congress: London, May 16 - 18 2018.
・May 17, 14:50, "Engineering cell therapeutics for controlled drug delivery - clinical case studies": Zami Aberman, Chairman and Chief Executive Officer, Pluristem.
※World Advanced Therapies & Regenerative Medicine Congress 2018, London: 16–18 May 2018
・May 17, 15:10 , "Placental derived cell for allogeneic treatment of solid cancer": Zami Aberman, Chairman and Chief Executive Officer, Pluristem.
※ASGCT 21st Annual Meeting: Chicago, IL, 16-19 May 2018.
・May 18, 9:00, "Short Activating RNAs. MTL-CEBPa has a Broad Range of Liver Disease Models and Encouraging Early Clinical Data in a Phase 1 Trial in HCC.": Nagy Habib (MiNA Therapeutics), Imperial College of London.
※ATS(American Thoracic Society) International Conference 2018: San Diego, CA USA, May 18-23 2018.
・May 21, 14:15, "Lung deflation and improvement of cardiac end-diastolic volumes with indacaterol/glycopyrronium reduce dyspnea and improve health status in hyperinflated COPD patients: the CLAIM study": Jens Hohlfeld.
※ASCO Annual Meeting: Chicago, IL, 1-5 June 2018.
・MiNA Therapeutics.
※The BIO International Convention 2018: Boston, MA, June 4-7, 2018.
・Yaky Yanay, President & Co-CEO, Pluristem. ※NovAlix Biophysics in Drug Discovery 2018: Boston, MA, USA, Jun 13-15, 2018
・June 14, 15:10, "Structural Insight into Allosteric Modulation of GPCRs": Dr Miles Congreve (Heptares)
※23rd Annual Congress of EHA (European Hematology Association): Stockholm, Sweden, 14-17 June 2018.
・MiNA Therapeutics.
※7th LSX CEO Forum (formerly Biotech and Money CEO Forum), London: 28 June 2018.
・14:15, Case Studies and Peer Review: "Sosei - AZ immune-oncology collaboration" - Malcolm Weir, Chief R&D officer, Sosei (former CEO Heptares) (Invited).
※Adrenoreceptors 2018, Receptor Structure Changes the Pharmacology Paradigm: Shizuoka, Japan, Jun 28-30, 2018
・Jun 28, "Structural insight driving commercial drug discovery": Rob Cooke (Heptares)
※18th World Congress of Basic and Clinical Pharmacology (WCP2018) Kyoto, Japan: July 1- 6, 2018.
・July 6, 10:20, "Biased apelin receptor agonists for cardiovascular disease" :Anthony P. Davenport, University of Cambridge, UK, (Heptares ORBIT Projects)
※日本核酸医薬学会 第４回年会, 博多, 日本：2018年7月9日〜11日.
・MiNA Therapeutics.
※Early Career Scientist Forum on GPCR Signal Transduction (ECSF-GPCR): Berlin, Germany, Jul 11-14, 2018
・Ali Jazayeri (Heptares)
・・・
※7th SCI/RSC Symposium on GPCRs in Medicinal Chemistry, Verona, Italy: September 10-12, 2018.
・Sep 11, 9:30 "Keynote: Application of structure-based drug design to peptidergic GPCRs": Miles Congreve, Heptares Therapeutics.
・Sep 12, 9:00 "Keynote: Shedding light on G protein bias: structures of GPCRs coupled to G proteins determined by cryo-EM and X-ray crystallography": Chris Tate, MRC LMB.
・・・ 五味さん資産200億以上あるやろ
お前ら人の買い単価調べる暇あったら自分の心配しろよw ごみさん、ツイッターで、今年に入ってコツコツ売ってますみたいな書き込みあったやん
つまり、今の売り本尊はゴミさんでしょ
一回ストップ安おこして、株数増やそうとしてるはず 今年に入ってってもう3ヶ月もコツコツ売り続けてたら変更報告書出してないとおかしいやろ gcnはごみだいすけだとおもうけど、すぐ消すからいちいち読んでな。売ってるっていってたの？ どう見ても有望な自社開発、自社販売用のパイプラインを有していることを、もっと評価すべきだと思うのですが。
まあ、その時が来たら、「あの時買っていれば今頃は…」なんていうことになるんですけどね。 こんな銘柄を大量保有してる時点で株のセンスが無いことは間違いないからな >>153
お前のほうがセンス有るなら五味さん以上に金持ってるんじゃね？
見せてみ？ っていうか、朝から何オラついてんだよ
バナナ食って糖分取れよ 今更そーせいって、乗り遅れすぎだろうｗ
もう２年前にピーク過ぎてるってのにｗ
センスなさすぎｗ 午前終わって、ぺプチ爆下げ、そーせいさん爆上げ
この違いについて述べよ。 メドレックスやラクオリア等の屑赤字バイオが下がってて飯ウマ いつの間にやらペプチの1/4の時価総額になってるなどうしてこうなったのやら 他のバイオが駄々下げの中、そーせいだけは暴騰
王者はちげえな ここ数日、電鉄、不動産、通信とそーせいが連動してるような。 >>169
五味さんより貧乏人のくせに煽ってるクズが多いからじゃねｗ >>171
お前が二桁で待つとかアホな事書くから
監視バイオでそーせいだけプラスやんけｗ サノビオンがCOPDの新薬アメリカで販売するけどそーせいへの影響はなしでいいのかなどうせ北米の売り上げほとんどないし ペプチドリームの株価の威を借りてそーせい批判するルサンチマンも居たねｗ 「卑屈」って言葉の意味は
「ずるい」とか「イケズ」の意味じゃないってことはもう覚えたか？売春婦の産んだ私生児・大久保婆よ？ｗｗ 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
Heptares is Currently Based in Welwyn Garden City but will be Moving to a brand New Research Facility at Granta Park (Cambridge) in July 2018.
Heptares has been Operating Approximately 130 Employees who will all be based in this New Research Facility.
Heptares and Imperial College seeking to rapidly advance drug discovery and translational research focused on multiple new and existing GPCR disease target.
Heptares Zurich: For our branch in Schlieren, we are looking for an enthusiastic and motivated personality by the middle of 2018 as biology lab technician (70-100%).
MiNA Therapeutics: Small Step Up to 1st Floor at the Translation & Innovation Hub on Imperial College London Campus.
・・・
※Heptares: We are recruiting for a "Cryo-Electron Microscopy Scientist" to join our biophysics group. (3/13 Closed)
※Imperial College London: Recruit a "Research Associate" to join the research programme in Imperial Heptares project, which focuses on the "Role of GPCRs in gastrointestinal physiology". (3/14Closed)
※Heptares: We are seeking a skilled "Computational Chemist" to Join the computational chemist team GPCR. (3/15 Closed)
※Heptares: We are growing our established Medicinal Chemistry Team and are seeking Scientist with Synthetic Organic Chemistry; One-Year Fixed Term Position. (4/3Closing→3/24Closed)
※Heptares: We are seeking a skilled organic chemist to join the "Medicinal Chemistry Team as a Research Scientist; Post-Doctoral, One-Year Fixed Term Position". (4/3Closed)
※Heptares: We are seeking to recruit a highly motivated "Analytical / Separation Scientist (Scientist/Research Scientist Grade)" GPCR. (4/3Closed)
・・・
※MiNA Therapeutics: Seeking two highly motivated and talented "Senior Technicians" to join its research team developing novel therapeutics in the field of RNA activation. (4/17 Closing)
※Imperial College London: We are seeking a Post-Doctoral Scientist "Research Associate" with a background in engineering or physical sciences. Heptares Partnership Project. (4/17 Closing)
※Heptares: We are now seeking to recruit an experienced Protein Biochemist for a One-Year Fixed term contract. (4/18 Closing)
※Heptares: By mid-2018, we are seeking for our site in Schlieren/Zurich (Switzerland) an enthusiastic and motivated "Laboratory Technician (70-100%)". (4/20 Closing)
※Heptares: We are currently seeking an experienced "Molecular Biologist" to join the protein engineering group working on GPCR structure determination to enable drug discovery efforts. (4/29Closing)
※Heptares: We are currently recruiting for a "Group Leader Protein Biochemistry" to join our team in Zurich. (5/5 Closing)
※Heptares: We are now seeking an enthusiastic Junior "Protein Biochemist " to join our team in Zurich. (5/5 Closing)
・・・ ※SOSEIの成長相場の動向：
2010/12/30 (終値_1350) ・(2010/10/15※最安値_650、2010/12/27最高値_1748)
2011/12/30 (終値_1271) ・(2011/3/15※最安値__693、2011/6/30最高値_1680)
2012/12/28 (終値_2087) ・(2012/6/6※最安値__950、2012/9/7最高値_2967)
2013/12/30 (終値_4315) ・(2013/1/4※最安値_2050、2013/5/7最高値_6100)
2014/_4/25 (終値_2058) 売残高36200 買残高 1053200 ・(2014/4/22最安値_1854)※[成長回収期の入口]ステージへ
2015/_2/20 (終値_3780) 売残高14200 買残高 1530800 ・(2015/3/16最安値_2851)※Heptares [成功の序章ステージ]
2015/10/30 (終値_4320) 売残高11400 買残高 2217900 ・(2015/9/24安値_3550)※米国承認[次なる飛躍ステージへ]
2015/11/27 (終値_6360) 売残高 14800 買残高 2552500 ・(2015/11/30終値_6060: Pfizer)※[上抜け圏へ]
2016/_4/25 (終値23230) 売残高39800 買残高 3404900 ・(2016/5/9最高値26180)※Allergan[強気相場]
2016/_6/24 (終値14720) 売残高10500 買残高 2486100 ・(2016/6/24安値12960)※[強気相場解除]→※[時間軸での調整局面へ]
2017/_1/_6 (終値14030) 売残高__300 買残高 2907100 ・(2017/2/13安値12400)※[強気相場解除後の時間軸調整は順調に推移]
2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(2017/4/4安値10280)※[振るい場・拾い場へ]
2017/_9/_8 (終値_8700) 売残高_1900 買残高 2037800 ・(2017/9/6最安値_8590)※[拾い場も順調に推移]
2018/_1/26 (終値12210) 売残高__900 買残高 1429100 ・(2017/12/6安値_9970)※[振るいも順調に推移]
2018/_3/30 (終値_8820) 売残高14400 買残高 2028000 ・(3/26最安値_8320)※[悪地合いにて再びの拾い場]
2018/_4/_2 (終値_8810) 5日線乖離(+0.80%) 25日線乖離(-3.97％) 75日線乖離(-14.72％) 200日線乖離(-15.91％) (安値_8770)
2018/_4/_3 (終値_8750) 5日線乖離(+0.46%) 25日線乖離(-4.21％) 75日線乖離(-15.13％) 200日線乖離(-16.39％) (安値_8550)
2018/_4/_4 (終値_8870) 5日線乖離(+1.16%) 25日線乖離(-2.51％) 75日線乖離(-13.77％) 200日線乖離(-15.15％) (安値_8700)
更なる成長の黎明期、上抜け圏にて、強気相場解除後の時間軸での調整は順調に推移。笑。
時間軸調整終盤、予定通りに推移、今回も面白くなりましたね。笑。
成長戦略の進捗と共に、次なる展開・進捗が楽しみです。笑。 >>185
言われなくても見てるだろw
ここしか見てない可能性もあるけどホルダーなめ過ぎ 【緊急】中国の報復関税でリスク回避の円買い (04/04)
16時ごろ、中国政府が106品目の米製品に対し、
500億ドル規模の追加報復関税を実施すると発表しました。
大豆に加え航空機なども25％関税の対象となったことで、
NYダウが-400ドル超急落（ボーイングは時間外で-4％超安）、
ドル円も一時105円台へ急落しています。
https://goo.gl/3PB2qQ.info もう精神状態保てなくてありもしないIRが見えるんじゃねーの >>194
俺なんか25,440円で2枚売り抜けたわｗ >>197
こういう書き込みしてネガキャンしてる奴って外資から幾らか貰ってんの？ 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
Heptares is Currently Based in Welwyn Garden City but will be Moving to a brand New Research Facility at Granta Park (Cambridge) in July 2018.
Heptares has been Operating Approximately 130 Employees who will all be based in this New Research Facility.
Heptares and Imperial College seeking to rapidly advance drug discovery and translational research focused on multiple new and existing GPCR disease target.
Heptares Zurich: For our branch in Schlieren, we are looking for an enthusiastic and motivated personality by the middle of 2018 as biology lab technician (70-100%).
MiNA Therapeutics: Small Step Up to 1st Floor at the Translation & Innovation Hub on Imperial College London Campus.
・・・
※新春展望Peter Bains, Sosei Group CEO：日本に軸足をおいた国際的なバイオ企業、そーせいを国際的なステージに展開へ。2018年主要テーマ：提携プログラムの進捗、自社パイプライン拡大、株主価値の向上。(1/2)
※SOSEI：Heptares社の研究者が炎症性疾患、神経変性疾患およびがんの重要な創薬ターゲットである補体C5a受容体の構造を解明。本研究は最新のNature誌にオンラインで公開。(1/5)
※Kymab Pipeline: KY1051: Discovery Research→"Pre-Clinical Development", KY1062 (New, Add): "Discovery Research" (1/6update)
※SOSEI：インペリアル･カレッジ・ロンドンと消化器疾患治療薬の研究開発を目的とした共同研究開発契約を締結。この提携では当社およびHeptares社で実施中の創薬および開発プログラムの支援も行う。(1/11up)
※Novartis Q4 & FY 2017: Ultibro: Q4 (120million, +26%cc), 2017FY (411million, +12%cc), Seebri: Q4 (42million, +4%cc), 2017FY (151million, +3%cc). First Clinical Study with "Concept2 Inhaler" is due to begin this Year. (1/24)
※SOSEI：｢シーブリおよびウルティブロ｣の2017年第4四半期(10月〜12月)の業績について。サノビオン社(10月にSeebri Neohaler販売開始)。｢ウルティブロ｣中国(12月に製造販売承認を取得)。(1/24)
※SOSEI株主通信：戦略面では、当社ビジネス・パイプライン双方を強化する投資と交渉を完了しただけでなく、海外における資金調達においても大きな成功を収めました。(2/2)
※AstraZeneca Full-Year and Q4: "AZD4635, Data Anticipated: 2018". Phase 1b will consist of an additional expansion phase in NSCLC at the combination MTD or maximum feasible dose. (2/2)
※あすか製薬 第3四半期決算：ノルレボ売上高：当期第3四半期9.3億円(前期第3四半期8.7億円)、対前年同四半期増減率6.5％、当期年間見込12.5億円(前期年間実績11.4億円) (2/5)
※Allergan Q4 and FY 2017: Pipeline Highlights 2017: Muscarinic Receptor M1: Ph 1, 2H 2017 and M4 Agonist: Entry Ph 1, 2H 2017. Rspectively: "Achieved". FY 2017 R&D Milestones: $15m.(2/6)
※Pluristem: "Our Expectations; Sosei CVC in Japan": "Pluristem is working hard to negotiate the best possible terms for a Japanese JV and will provide an update upon reaching an agreement." (2/7)
※SOSEI：AstraZeneca社とのがん免疫療法分野の共同開発プログラムが順調に進行。後期第I相試験が開始。2019年後半に完了する予定。2018年第1四半期に後期第I相/第II相臨床試験(新規併用療法)を開始予定。(2/8)
※ペプチドリーム第2四半期決算：Heptares戦略的提携、この共同研究では、両社のもつ業界屈指のプラットフォーム技術を集結。両社での取組みは着実に進んでおり、近く進捗状況の報告が提供できる。(2/13)
※SOSE 第3四半期決算：研究開発費3,456百万円(48.4％増加)97.1%は英国活動。日本におけるHTL0018318(DLB)の臨床試験開始に向けた準備を含め、自社独自のパイプライン拡大に向けた投資も継続増加。(2/14)
※SOSEI：ウルティブロ投与治療により肺過膨張を伴うCOPD罹患患者の心臓機能及び肺機能が大幅に改善。2剤配合気管支拡張薬が心臓機能へ与える影響を調査した初めての試験(CLAIM)。(2/22)
※日本商標出願(Sosei)：SOSeIHEPTARES (https://pbs.twimg.com/media/DXNlWr8UMAAQbNa.jpg) 出願日:2018/2/9、出願人:そーせいグループ株式会社 (2/27公開) ※Business Weekly Cambridge: Granta Park’s owner BioMed Realty: "The next move for Granta Park will be to welcome life science company Heptares in the summer". (3/2)
※JITSUBO：インドNeulandとの包括的パートナーシップに向けた覚書締結。日本の先端技術とインドの高い製造能力・豊富な実績の国際連携で、大きなシナジーを創出できると確信しております。(3/5)
※Metrion Biosciences (Granta Park): Announced it has appointed "Dr Barry Kenny (Non-Executive Director.)" to its Board of Directors. "Dr Kenny is Chief Business Officer of Heptares, now part of Sosei Group." (3/5)
※ClinicalTrial(HTL0018318-202): A Phase 1b, Multi-center Study to Determine the Safety and Tolerability of HTL0018318 in Subjects with AD. "Actual Start: 2017/11/10". Estimated Completion: 2018/8. (3/7up: New Trial Record)
※MiNA Therapeutics: Announces Publication of Pre-Clinical Data Supporting Therapeutic Potential of Clinical Candidate MTL-CEBPA in Liver Cancer and Liver Disease. (3/9)
※SOSEI：片頭痛、その他重度の頭痛に対する治療薬である新規低分子CGRP拮抗薬のグローバルにおける開発・販売の権利をTeva社が返還。臨床開発の段階へ迅速に進められる状態にある。(3/13)
※SOSEI個人投資家説明会(資料)：レビー小体型認知症を適用としたHTL001831の開発(日本)：ティム・タスカー、構造生物学及び研究開発パイプラインについて：マルコム・ウィアー。(3/14up)
※ClinicalTrial: A Phase 1b, FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil±Memantine) for the Treatment of Participants With Mild to Moderate AD. Start Changed: 2/20→"2018/4/13". (3/14update)
※四季報：自社パイプライン：他社との提携・導出に加え、自社販売視野に入れた開発候補７品目保有。18年内にレビー小体型認知症薬は2相、神経性疾患薬は1相入り目指す。(3/16更新)
※SOSEI個人投資家説明会(動画)：ピーター・ベインズ挨拶、HTL001831の開発(日本)、研究開発パイプライン。http://www.sosei.com/ir/library/results_briefing.html (3/19up)
※ClinicalTrials: Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies. Changed Study Completion: 2019/8/21→"2019/12/23"[Anticipated] (3/20update)
※Vectura 2017 Preliminary Results: Ultibro and Seebri, 2017 combined net sales of $562 million and Vectura recognised £17.3 million of Total Royalties for sales of these products. (3/21)
※Vectura Earnings Call: "Ultibro growing at almost 21% year-on-year.", "In our 2018 outlook strong growth of revenues driven by Ultibro in particular." (3/21)
※四季報Online：新薬開発で大手もベンチャーも意気込む春。ベンチャーで承認申請が期待される新薬候補：既に承認申請済みの製品群では、そーせいグループの口腔咽頭カンジダ症治療薬「SO1105」が期待。(3/24)
※Fudan University: Discovered Small Molecule Drug Candidates for the Treatment of Huntington's Disease: It has also attracted the attention of Hepcares, and entered into the signing of a cooperation agreement. (3/28)
・・・
※Novartis First Quarter Results 2018: (4/19)
※Allergan Q1 2018 Earnings Release: (4/30)
※Pluristem Q3 2018 Earnings Release: (5/ )
※あすか製薬 平成30年3月期決算発表: (5月中旬)
※SOSEI 平成30年3月期決算発表: (5月中旬)
※ペプチドリーム 平成30年6月期第3四半期決算発表: (5/16予定)
※AstraZeneca Q1 2018 Earnings Release: (5/18)
・・・ ※SOSEIの成長相場の動向：
2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(2017/4/4安値10280)※[振るい場・拾い場へ]
2017/_9/_8 (終値_8700) 売残高_1900 買残高 2037800 ・(2017/9/6最安値_8590)※[拾い場も順調に推移]
2017/11/17 (終値12190) 売残高_3100 買残高 1532100 ・(2017/10/4安値_9090)※[時間軸調整終盤、予定通りに推移]
2018/_1/26 (終値12210) 売残高__900 買残高 1429100(-214600) ・(2017/12/6安値_9970)※[振るいも順調に推移]
2018/_2/_2 (終値11650) 売残高__300 買残高 1482300(_+53200) ・(1/31安値11440)
2018/_2/_9 (終値10330) 売残高12500 買残高 1524700(_+42400) ・(2/6安値_9700)
2018/_2/16 (終値_9920) 売残高11800 買残高 1591200(_+66500) ・(2/14安値_9700)
2018/_2/23 (終値_9620) 売残高_9800 買残高 1773800(+182600) ・(2/22安値_9460)
2018/_3/_2 (終値_9380) 売残高10500 買残高 1854600(_+80800) ・(3/2安値_9270)
2018/_3/_9 (終値_9510) 売残高10500 買残高 1794400(_-60200) ・(3/5安値_8780)※[悪地合いにて再びの拾い場]
2018/_3/16 (終値_9070) 売残高13500 買残高 2019900(+225500) ・(3/16安値_9070)
2018/_3/23 (終値_8590) 売残高14100 買残高 2046500(_+26600) ・(3/23安値_8580)
2018/_3/30 (終値_8820) 売残高14400 買残高 2028000(_-18500)※4/3up ・(3/26最安値_8320)
2018/_4/_2 (終値_8810) 5日線乖離(+0.80%) 25日線乖離(-3.97％) 75日線乖離(-14.72％) 200日線乖離(-15.91％) (安値_8770)
2018/_4/_3 (終値_8750) 5日線乖離(+0.46%) 25日線乖離(-4.21％) 75日線乖離(-15.13％) 200日線乖離(-16.39％) (安値_8550)
2018/_4/_4 (終値_8870) 5日線乖離(+1.16%) 25日線乖離(-2.51％) 75日線乖離(-13.77％) 200日線乖離(-15.15％) (安値_8700)
更なる成長の黎明期、上抜け圏にて、強気相場解除後の時間軸での調整は順調に推移。笑。
時間軸調整終盤、予定通りに推移、今回も面白くなりましたね。笑。
成長戦略の進捗と共に、次なる展開・進捗が楽しみです。笑。 前はなんとも思ってなかったけど、今はただ気持ち悪い 俺なんともないわ
長文コピペなんて匿名掲示板のどこにでもある
いわば路傍の石のようなもの。
そんなものにまでいちいち気に触るような精神状態は
うつ病のなりかけ。 トランプ政権は貿易戦争を巡る懸念の沈静化に動いている BBG
きたああああああああああああああああああああああああああああああああああああああああああああああああああああああ レス荒らしの基CHI外を援護する奴ってどうかしてるぜ
こいつらもろとも消えてもらいてえ >>216
擁護してる奴はノンホルでしょ？
クズはどこまでもクズｗ >>218
＋140円で二試合連続ホームランの大谷もビックリｗ
ルサンチメンズはダンマリｗ 今んとこ、ぺプチは爆下げ、そーせいさんは爆上げ
この違いについて述べよ。 ぺプチは、ぁほるだーの利益確定で下げて、
そーせいさんは、空売り隊の利益確定で上げてる
こんな感じかなぁー。。。？ ペプチ二年で3倍弱
そーせい二年で3分の1
とほほ ［ワシントン ４日 ロイター］ - トランプ米大統領は４日、米中は貿易戦争に入っていないとの見解を示した。
トランプトーンダウン
きたああああああああああああああああああああああああああああああああああああああああああああああああああああああ いつまでジャイアンやってんだろ
社長と大統領は違うって事をそろそろ分かったほうがいいな やっぱアホみたいに上げすぎだろ 売りストロングほーるど ＾茶＾ そーせいはせめてペプチの半額くらいにはなれるように頑張れよ ■ このスレッドは過去ログ倉庫に格納されています
